Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
Kaistha BP, Kar G, Dannhorn A, Watkins A, Opoku-Ansah G, Ilieva K, Mullins S, Anderton J, Galvani E, Garcon F, Lapointe JM, Brown L, Hair J, Slidel T, Luheshi N, Ryan K, Hardaker E, Dovedi S, Kumar R, Wilkinson RW, Hammond SA, Eyles J. Kaistha BP, et al. Among authors: luheshi n. Cancer Biol Ther. 2024 Dec 31;25(1):2296048. doi: 10.1080/15384047.2023.2296048. Epub 2024 Jan 11. Cancer Biol Ther. 2024. PMID: 38206570 Free PMC article.
A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selection.
Shahraz A, Penney M, Candido J, Opoku-Ansah G, Neubauer M, Eyles J, Ojo O, Liu N, Luheshi NM, Phipps A, Vishwanathan K. Shahraz A, et al. Among authors: luheshi nm. CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1670-1681. doi: 10.1002/psp4.13204. Epub 2024 Jul 23. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 39041713 Free PMC article.
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Kinneer K, Wortmann P, Cooper ZA, Dickinson NJ, Masterson L, Cailleau T, Hutchinson I, Vijayakrishnan B, McFarlane M, Ball K, Davies M, Lewis A, Huang Y, Rosenbaum AI, Yuan J, Chesebrough J, Anderton J, Monks N, Novick S, Wang J, Dimasi N, Christie RJ, Sabol D, Tosto FA, Wallez Y, Leo E, Albertella MR, Staniszewska AD, Tice DA, Howard PW, Luheshi N, Sapra P. Kinneer K, et al. Among authors: luheshi n. Clin Cancer Res. 2023 Mar 14;29(6):1086-1101. doi: 10.1158/1078-0432.CCR-22-2630. Clin Cancer Res. 2023. PMID: 36355054
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro GA, Alexander AF, McGeary MK, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss SA, Olino K, Kaech SM, Kluger HM, Miller-Jensen K, Bosenberg M. Krykbaeva I, et al. Among authors: luheshi n. Cancer Immunol Res. 2023 Oct 4;11(10):1332-1350. doi: 10.1158/2326-6066.CIR-22-0699. Cancer Immunol Res. 2023. PMID: 37478171
Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer.
Hughson AL, Hannon G, Salama NA, Vrooman TG, Stockwell CA, Mills BN, Garrett-Larsen J, Qiu H, Katerji R, Benoodt L, Johnston CJ, Murphy JD, Kruger E, Ye J, Gavras NW, Keeley DC, Qin SS, Lesch ML, Muhitch JB, Love TMT, Calvi LM, Lord EM, Luheshi N, Elyes J, Linehan DC, Gerber SA. Hughson AL, et al. Among authors: luheshi n. Mol Ther Nucleic Acids. 2024 Sep 30;35(4):102350. doi: 10.1016/j.omtn.2024.102350. eCollection 2024 Dec 10. Mol Ther Nucleic Acids. 2024. PMID: 39469666 Free PMC article.
Local Delivery of SBRT and IL12 by mRNA Technology Overcomes Immunosuppressive Barriers to Eliminate Pancreatic Cancer.
Hughson AL, Hannon G, Salama NA, Vrooman TG, Stockwell CA, Mills BN, Garrett-Larsen J, Qiu H, Katerji R, Benoodt L, Johnston CJ, Murphy JD, Kruger E, Ye J, Gavras NW, Keeley DC, Qin SS, Lesch ML, Muhitch JB, Love TMT, Calvi LM, Lord EM, Luheshi N, Elyes J, Linehan DC, Gerber SA. Hughson AL, et al. Among authors: luheshi n. bioRxiv [Preprint]. 2023 Nov 2:2023.10.30.564833. doi: 10.1101/2023.10.30.564833. bioRxiv. 2023. PMID: 37961513 Free PMC article. Preprint.
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ, Percival-Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, McGlinchey K, Adjei G, Watkins A, Machiesky L, Chen W, Andrews J, Groves M, Morrow M, Stewart RA, Leinster A, Wilkinson RW, Hammond SA, Luheshi N, Dobson C, Oberst M. Schofield DJ, et al. Among authors: luheshi n. MAbs. 2021 Jan-Dec;13(1):1857100. doi: 10.1080/19420862.2020.1857100. MAbs. 2021. PMID: 33397194 Free PMC article.
Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action.
Austin M, Burschowsky D, Chan DTY, Jenkinson L, Haynes S, Diamandakis A, Seewooruthun C, Addyman A, Fiedler S, Ryman S, Whitehouse J, Slater LH, Hadjinicolaou AV, Gileadi U, Gowans E, Shibata Y, Barnard M, Kaserer T, Sharma P, Luheshi NM, Wilkinson RW, Vaughan TJ, Holt SV, Cerundolo V, Carr MD, Groves MAT. Austin M, et al. Among authors: luheshi nm. MAbs. 2020 Jan-Dec;12(1):1801230. doi: 10.1080/19420862.2020.1801230. MAbs. 2020. PMID: 32880207 Free PMC article.
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, Burke S, Garcon F, Mishra A, Gurumurthy S, Watkins A, Arnold K, Moynihan J, Clancy-Thompson E, Mulgrew K, Adjei G, Deschler K, Potz D, Moody G, Leinster DA, Novick S, Sulikowski M, Bagnall C, Martin P, Lapointe JM, Si H, Morehouse C, Sedic M, Wilkinson RW, Herbst R, Frederick JP, Luheshi N. Hewitt SL, et al. Among authors: luheshi n. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298. doi: 10.1158/1078-0432.CCR-20-0472. Epub 2020 Aug 17. Clin Cancer Res. 2020. PMID: 32817076
25 results